

Title (en)
TREATMENT OF TUMOURS

Title (de)
BEHANDLUNG VON TUMOREN

Title (fr)
TRAITEMENT DE TUMEURS

Publication
EP 1379542 A2 20040114 (EN)

Application
EP 02704017 A 20020311

Priority
• SE 0200443 W 20020311
• SE 0100857 A 20010313

Abstract (en)
[origin: WO02072003A2] The present invention relates to steroid derivatives for use as medicaments. More specifically, the invention also relates to the use of a steroid derivative of 5-androstene-, 5-pregnenolone or corresponding saturated derivatives (androstane- or pregnane-) in the manufacture of a medicament for the treatment of a benign and/or malignant tumour, which medicament is capable of interrupting disturbances in Wnt-signaling, such as cell-cycle arrest in G1-phase, and/or providing an angiostatic effect. Examples of such steroid derivatives are DELTA -5-androstene-17 alpha -ol, androstane-17 alpha -ol-pregnane-17 alpha -ol or pregnane-17 alpha -ol derivatives. In a further aspect, the invention relates to a method of producing a medicament for the treatment of a benign and/or malignant tumour and/or an inflammatory condition comprising the steps of contacting 5-androstane-3ss,17 alpha -diol or androstane-3ss alpha -diol, an enzyme and a sulfotransferase to provide 5-androstene-17 alpha -ol-3ss-sulfate or corresponding androstane derivative (17 alpha -AEDS or 17-AADS); and mixing the 17 alpha -AEDS or 17 alpha -AADS so produced with a suitable carrier; whereby a medicament which is capable of acting as a ligand to perox-isome proliferator-activated receptor- gamma (PPAR gamma) is produced.

IPC 1-7
C07J 1/00; **C07J 5/00**; **A61K 31/568**; **A61K 31/57**; **A61P 35/00**

IPC 8 full level
A61K 47/36 (2006.01); **C07J 1/00** (2006.01); **A61K 31/37** (2006.01); **A61K 31/56** (2006.01); **A61K 31/568** (2006.01); **A61K 31/569** (2006.01); **A61K 31/57** (2006.01); **A61K 45/06** (2006.01); **A61P 1/04** (2006.01); **A61P 19/02** (2006.01); **A61P 25/00** (2006.01); **A61P 27/02** (2006.01); **A61P 29/00** (2006.01); **A61P 35/00** (2006.01); **A61P 35/04** (2006.01); **A61P 37/02** (2006.01); **A61P 43/00** (2006.01); **C07J 5/00** (2006.01); **C07J 31/00** (2006.01)

CPC (source: EP)
A61K 31/37 (2013.01); **A61K 31/568** (2013.01); **A61K 31/569** (2013.01); **A61K 31/57** (2013.01); **A61K 45/06** (2013.01); **A61P 1/04** (2017.12); **A61P 19/02** (2017.12); **A61P 25/00** (2017.12); **A61P 27/02** (2017.12); **A61P 29/00** (2017.12); **A61P 35/00** (2017.12); **A61P 35/04** (2017.12); **A61P 37/02** (2017.12); **A61P 43/00** (2017.12); **C07J 1/0014** (2013.01); **C07J 31/00** (2013.01)

Citation (search report)
See references of WO 02072003A2

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)
WO 02072003 A2 20020919; **WO 02072003 A3 20030220**; AU 2002237613 B2 20080103; CA 2440973 A1 20020919; EP 1379542 A2 20040114; JP 2004524325 A 20040812; SE 0100857 D0 20010313

DOCDB simple family (application)
SE 0200443 W 20020311; AU 2002237613 A 20020311; CA 2440973 A 20020311; EP 02704017 A 20020311; JP 2002570963 A 20020311; SE 0100857 A 20010313